Portfolio

Company Announcements

Completion of Acquisition

Related Companies

By LSE RNS

RNS Number : 8775S
Medaphor Group PLC
06 October 2017
 

MedaPhor Group plc

("MedaPhor" or the "Group" or the "Company")

 

Completion of Acquisition

Total Voting Rights

Director/PDMR Shareholding

 

MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that following admission today of 56,477,285 new ordinary shares of 1 pence each ("Ordinary Shares") relating to the placing to raise approximately £5.5 million and the Company's proposed acquisition of Intelligent Ultrasound Limited for a total consideration of up to £3.6 million, both the placing and the acquisition have completed.

 

Following admission, the share capital of the Company will consist of 90,701,443 Ordinary Shares.  Therefore, the total number of voting rights in the Company is 90,701,443 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

 

The Company makes the following disclosures in respect of the participation in the Placing by persons discharging managerial responsibilities and persons closely associated, in accordance with article 19(3) of the Market Abuse Regulation:

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

IP Group plc

2

Reason for the notification

a)

Position/status

Person closely associated - David Baynes, Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MedaPhor Group plc

 

b)

LEI

N/A

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 1 pence each

Identification code

ISIN: GB00BN791Q39

b)

Nature of the transaction

Purchase of ordinary shares of 1 pence each as part of a placing

Consideration payable in ordinary shares of 1 pence each as part of an acquisition

c)

 

Price(s) and volume(s)

 

 

 

 


 

Price(s)

Volume(s)

 


 

12.50 pence

16,000,000

 


 

16.22 pence

5,055,320

 


 

 

 

 

 

d)

 

Aggregated information

 



- Aggregated volume

16,000,000 (being the placing shares)



- Price

£2,000,000

 

- Aggregate volume

 

- Price

 

 

 

5,055,320 (being the consideration shares)

 

£819,972.90

e)

Date of the transaction

6 October 2017

f)

Place of the transaction

XLON

 

 

Enquiries:

 

MedaPhor Group plc

www.medaphor.com

Stuart Gall, CEO

Tel: +44 (0)29 2075 6534

 

 

Cenkos Securities

Tel:  +44 (0)20 7397 8900

Bobbie Hilliam (Nominated Advisor)

 

Michael Johnson / Julian Morse (Corporate Broking)

 


 

Walbrook PR

Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001

 

About MedaPhor (www.medaphor.com)

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops advanced hi-fidelity haptic and manikin based training simulators, clinical image analysis software tools, augmented reality based needle guidance software and artificial intelligence based automated scanning software for all medical practitioners.

 
Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:

 
Ultrasound Simulation and Training

 
Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Point-of-Care simulator platform (launching January 2018). Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.

 
Intelligent Ultrasound

 
Focuses on developing augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. ScanNav uses machine-learning based algorithms to automatically access and grade ultrasound images to provide scan assessment and audit of obstetric scanning. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFSUFWIFWSEIS

Top of Page